ABSTRACT
Suppose you have just read a report in your favorite medical journal. The success rates were said to be 50% with a new treatment for Disease D, and 33% in the control group, receiving the customary old treatment. You now have a clinical challenge: Should you beginning the new treatment instead of the old one for patients with Disease D?
